Rosuvastatin attenuates atrial structural remodelling in rats with myocardial infarction through the inhibition of the p38 MAPK signalling pathway

Heart Lung and Circulation

Volumn 24, Issue 4, 2015, Pages 386-394

  Wang, Mengzan ^a,b   Li, Zhiyuan ^a,c   Zhang, Xiaohong ^a   Xie, Xinxing ^a   Zhang, Yujiao ^a   Wang, Ximin ^a   Hou, Yinglong ^a  

^a SHANDONG UNIVERSITY   (China)

^b LIAOCHENG PEOPLE'S HOSPITAL   (China)

^c Third Department of Internal Medicine   (China)

Author keywords

Atrial structural remodeling; Myocardial infarction; P38 MAPK; Rosuvastatin

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN; ROSUVASTATIN; TORASEMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATRIAL STRUCTURAL REMODELLING; CARDIOVASCULAR PARAMETERS; COLLAGEN VOLUME FRACTION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG MEGADOSE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART ATRIUM FIBRILLATION; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; LEFT VENTRICULAR FRACTIONAL SHORTENING; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; HEART ATRIUM REMODELING; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; ATRIAL REMODELING; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MAP KINASE SIGNALING SYSTEM; MYOCARDIAL INFARCTION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, WISTAR; ROSUVASTATIN CALCIUM;

EID: 84925168091     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2014.11.012     Document Type: Article

References (30)

1. Beyerbach D.M., Zipes D.P. Mortality as an endpoint in atrial fibrillation. Heart Rhythm 2004, 1:B8-B18.
2. Corradi D. Atrial fibrillation from the pathologist's perspective. Cardiovasc Pathol 2014, 23:71-84.
3. Cherniavskiĭ A.M., Rakhmonov S.S., Pak I.A., Kareva IuE. The role of autonomous nervous system in the development of atrial fibrillation. Klin Med (Mosk) 2013, 91:16-20.
4. Pan Z., Zhao W., Zhang X., Wang B., Wang J., Sun X., et al. Scutellarin alleviates interstitial fibrosis and cardiac dysfunction of infarct rats by inhibiting TGFβ1 expression and activation of p38-MAPK and ERK1/2. Br J Pharmacol 2011, 162:688-700.
5. Wang X., Lv H., Gu Y., Wang X., Cao H., Tang Y., et al. Protective effect of lycopene on cardiac function and myocardial fibrosis after acute myocardial infarction in rats via the modulation of p38 and MMP-9. J Mol Histol 2014, 45:113-120.
6. Lee Y.L., Blaha M.J., Jones S.R. Statin therapy in the prevention and treatment of atrial fibrillation. Journal of Clinical Lipidology 2011, 5:18-29.
7. Node K., Fujita M., Kitakaze M., Hori M., Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003, 108:839-843.
8. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001, 104:982-985.
9. Veeraveedu PT1, Watanabe K., Ma M., Thandavarayan R.A., Palaniyandi S.S., Yamaguchi K., et al. Comparative effects of torsemide and furosemide in rats with heart failure. Biochem Pharmacol 2008, 75:649-659.
10. Qin Y.W., Ye P., He J.Q., Sheng L., Wang L.Y., Du J. Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a "Western-style diet" by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels. Acta Pharmacologica Sinica 2010, 31:1350-1358.
11. Aoyama T., Takimoto Y., Pennica D., Inoue R., Shinoda E., Hattori R., et al. Augmented expression of cardiotrophin-1 and its receptor component, gp130, in both left and right ventricles after myocardial infarction in the rat. J Mol Cell Cardiol 2000, 32:1821-1830.
12. Hu X., Sun A., Xie X., Huang Z., Jia J., Yao R., et al. Rosuvastatin changes cytokine expressions in ischemic territory and preserves heart function after acute myocardial infarction in rats. J Cardiovasc Pharmacol Ther. 2013, 18(2):162-176.
13. Li J., Xia W., Feng W., Qu X. Effects of rosuvastatin on serum asymmetric dimethylarginine levels and atrial structural remodeling in atrial fibrillation dogs. Pacing Clin Electrophysiol. 2012, 35(4):456-464.
14. Tsai CF1, Yang S.F., Chu H.J., Ueng K.C. Cross-talk between mineralocorticoid receptor/angiotensin II type 1 receptor and mitogen-activated protein kinase pathways underlies aldosterone-induced atrial fibrotic responses in HL-1 cardiomyocytes. Int J Cardiol. 2013, 169(1):17-28.
15. Burstein B., Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008, 51:802-809.
16. Patti G., Chello M., Candura D., Pasceri V., D'Ambrosio A., Covino E., et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 2006, 114:1455-1461.
17. Adam O., Neuberger H.R., Böhm M., Laufs U. Prevention of Atrial Fibrillation With 3-Hvdroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors. Circulation 2008, 118:1285-1293.
18. Karimi A., Bidhendi L.M., Rezvanfard M., Bina P., Yousefi A., Molai M., et al. The effect of a high dose of atorvastatin on the occurrence of atrial fibrillation after coronary artery bypass grafting. Ann Thorac Surg 2012, 94:8-14.
19. Samadikhah J., Golzari S.E., Sabermarouf B., Karimzadeh I., Tizro P., Mohammad Khanli H., et al. Efficacy of Combination Therapy of Statin and Vitamin C in Comparison with Statin in the Prevention of Post-CABG Atrial Fibrillation. Adv Pharm Bull 2014, 4:97-100.
20. Liu T., Korantzopoulos P., Li L., Li G. Preventive effects of rosuvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials. Int J Cardiol 2013, 167:3058-3060.
21. Adhikary L., Chow F., Nikolic-Paterson D.J., Stambe C., Dowling J., Atkins R.C., et al. Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. Diabetologia 2004, 47:1210-1222.
22. Matsumoto-Ida M., Takimoto Y., Aoyama T., Akao M., Takeda T., Kita T. Activation of TGF-β1-TAK1-p38 MAPK pathway in spared cardiomyocytes is involved in left ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 2006, 290:H709-H715.
23. Yin H., Zhang J., Lin H., Wang R., Qiao Y., Wang B., et al. p38 Mitogen-Activated Protein Kinase Inhibition Decreases TNFalpha Secretion and Protects Against Left Ventricular Remodeling in Rats with Myocardial Ischemia. Inflammation 2008, 31:65-73.
24. Thandavarayan R.A., Watanabe K., Ma M., Gurusamy N., Veeraveedu P.T., Konishi T., et al. Dominant-negative p38 mitogen-activated protein kinase prevents cardiac apoptosis and remodeling after streptozotocin-induced diabetes mellitus. Am J Physiol Heart Circ Physiol 2009, 297:H911-H919.
25. Bao X.M., Wu C.F., Lu G.P. Atorvastatin inhibits homocysteine-induced oxidative stress and apoptosis in endothelial progenitor cells involving Nox4 and p38MAPK. Atherosclerosis 2010, 210:114-121.
26. Chen J., Mehta J.L. Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. American Journal of Physiology, Heart and Circulatory Physiology 2006, 291:H1738-H1745.
27. Yeh C.C., Li H., Malhotra D., Turcato S., Nicholas S., Tu R., et al. Distinctive ERK and p38 signaling in remote and infarcted myocardium during post-MI remodeling in the mouse. J Cell Biochem 2010, 109:1185-1191.
28. Rodriguez-Barbero A., Obreo J., Yuste L., Montero J.C., Rodríguez-Peña A., Pandiella A., et al. Transforming growth factor-beta 1 induces collagen synthesis and accumulation via p38 mitogen-activated protein kinase (MAPK) pathway in cultured L(6)E(9) myoblasts. FEBS Lett 2002, 513:282-288.
29. Akiyama-Uchida Y., Ashizawa N., Ohtsuru A., Seto S., Tsukazaki T., Kikuchi H., et al. Norepinephrine enhances fibrosis mediated by TGF-beta in cardiac fibroblasts. Hypertension 2002, 40:148-154.
30. Liao P., Georgakopoulos D., Kovacs A., Zheng M., Lerner D., Pu H., et al. The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci USA 2001, 98:12283-12288.